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ABSTRACT
Introduction: The prescribing information for
daptomycin recommends discontinuing statin
therapy during receipt of daptomycin. The
literature supporting this recommendation is
sparse. The objectives of this study were to
examine the impact of 3-hydroxy-3-methyl-
glutaryl-CoA (HMG-CoA) reductase inhibitors
(statins) on creatine phosphokinase (CPK)
elevations and mortality among patients
receiving daptomycin therapy.
Methods: A retrospective cohort study was
performed among daptomycin recipients in
the Upstate New York Veterans’ Healthcare
Administration from September 15, 2003 to
July 1, 2013. Inclusion criteria were: (1)
daptomycin for C48 h, (2) availability of
baseline CPK value and (3) [1 CPK level
measurement taken while on therapy. The
following were extracted from medical records:
demographics, comorbidities, laboratory data,
medication history (daptomycin, statins and
concomitant drugs known to increase CPK),
Acute Physiology and Chronic Health
Evaluation (APACHE)-II score and vital status
at 30 days. The exposure of interest was use of
statins. The primary outcome was CPK
elevation defined as a CPK value C3 times the
upper limit of normal (ULN) if baseline CPK was
normal, and C5 times ULN if baseline CPK was
elevated. The secondary outcome was death
within 30 days of commencing daptomycin.
Results: A total of 233 patients were included
in this analysis. Among these patients, 53
received concomitant statin therapy. Most
baseline clinical characteristics were similar
between statin recipients and non-recipients.
Five (2.1%) patients experienced a CPK
elevation; 3/53 (5.7%) were statin recipients
and 2/180 (1.1%) received daptomycin alone
(p = 0.08). All patients with CPK elevations had
normal baseline CPK values. No effect
modification was observed by use of other
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concomitant medications known to increase
CPK values. Death was observed more
frequently among statin non-recipients
(17.2%) than recipients (9.4%).
Conclusions: Among patients receiving
daptomycin, no significant difference was
observed in frequency of CPK elevation
between statin recipients and non-recipients.
Keywords: Daptomycin; Mortality; Myopathy;
Outcomes; Statins; Toxicity
INTRODUCTION
Daptomycin is an antibiotic used to treat
complicated infections caused by aerobic
Gram-positive organisms, including
methicillin-resistant Staphylococcus aureus
(MRSA) and vancomycin-resistant Enterococcus
(VRE) [1]. The use of this agent has somewhat
been limited by its toxicity profile, specifically
the potential to cause elevations in creatine
phosphokinase (CPK) [1]. This is a meaningful
outcome as CPK elevation may be indicative of
skeletal muscle toxicity and, in extreme
circumstances, life-threatening conditions
such as rhabdomyolysis [2].
The potential to cause elevations in CPK may
be enhanced when daptomycin exposure is
altered (e.g., higher doses or diminished
creatinine clearance) [3] or when used in
combination with other agents that also
increase CPK [1]. Among medications known
to elevate CPK, HMG-CoA reductase inhibitors
(statins) are commonly used [4]. The prescribing
information for daptomycin specifically
recommends discontinuing statin therapy
during receipt of daptomycin [1]. However,
the literature supporting this recommendation
is sparse, and there has not been a thorough
assessment to determine if there is an increased
frequency of CPK elevations between statin
recipients and non-recipients receiving
daptomycin.
The primary objective of this study was to
compare the incidence of CPK elevation
between recipients and non-recipients of
statins receiving daptomycin. The secondary
objective was to assess the relationship
between concomitant statin therapy and
mortality.
METHODS
Study Design and Population
A retrospective cohort study was performed
among patients in the Upstate New York
Veterans’ Affairs Healthcare Network or
Veterans’ Integrated Service Network (VISN)-2
from September 15, 2003 to July 1, 2013.
Inclusion criteria were: (1) receipt of
daptomycin for C48 h, (2) availability of
baseline CPK value and (3) [1 CPK level
measurement taken while on therapy.
Information was only gathered for patients
receiving daptomycin for their first treatment
course during the study period. This
retrospective study was approved by the
Samuel S. Stratton Veterans’ Affairs Research
and Development Committee and the
Institutional Review Board.
The retrospective analysis in this article does
not involve any new studies of human subjects
performed by any of the authors.
Data Collection
Data were extracted by trained reviewers and
included demographics, comorbidities,
laboratory data including CPK level and
creatinine clearance (CrCL) [5], previous
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hospitalizations within 90 days, inpatient
location [intensive care unit (ICU) versus non-
ICU], concomitant medications associated with
CPK elevations, length of hospital stay, CPK
levels and mortality. With regard to
daptomycin use, information collected
included the dose, frequency (standard
frequency of daptomycin dosing is every 24 h
or every 48 h) and duration of daptomycin
therapy.
Demographic characteristics included age,
sex, weight and body mass index. Data on
comorbidities experienced by each patient were
collected, and included organ transplant,
musculoskeletal disease, hypertension, cancer,
congestive heart failure, renal impairment, liver
disease, chronic obstructive pulmonary disease,
cerebrovascular accident, and alcoholism. Use
of concomitant medications known to increase
CPK was captured for each patient during the
time of daptomycin administration. These
medications included: corticosteroids,
phenothiazine antipsychotics, antiretrovirals,
colchicine, chloroquine, hydroxychloroquine
and recreational drug use. The specific statin
used during daptomycin therapy was
documented.
Microbiologic culture data were collected
prior to the start of daptomycin. The
indication for treatment was categorized as
skin and skin structure, osteomyelitis,
endocarditis, bacteremia or empiric therapy.
Severity of illness at the initiation of therapy
was calculated using the Acute Physiology and
Chronic Health Evaluation (APACHE)-II [6].
Statin Exposure
The exposure of interest in this study was the
use of statin therapy while receiving
daptomycin. The specific statins that were
available during the study period were:
simvastatin, atorvastatin, pravastatin,
rosuvastatin, lovastatin, fluvastatin and
pitavastatin.
Outcomes
The outcomes examined were: (1) CPK
elevation and (2) death within 30 days of
commencing daptomycin. The definition of
CPK elevation was adapted from Bhavnani
et al. [3] CPK levels were assessed from day 4
of daptomycin therapy to 3 days after
daptomycin was discontinued. For patients
with a normal CPK level at baseline, CPK
elevation was defined as a level C3 times the
upper limit of normal (ULN). Based on the
reference range at the Veterans’ Affairs Medical
Center, this corresponded to CPK values in
excess of 696 units/L. For patients with an
abnormal CPK level at baseline, CPK elevation
was defined as a level C5 times ULN
(1,160 units/L). Both definitions were based on
two sequential measurements. Stratified
analyses were performed between patients
with normal versus abnormal baseline CPK
values and CrCL C versus\30 mL/min.
Statistical Analyses
In the bivariate analyses, categorical variables
were assessed using Chi square and Fisher’s
exact test. For continuous variables, Student’s
T and Mann–Whitney U tests were used. The
log-rank test was used to compare frequency of
CPK elevations, integrated over time, between
statin recipients and non-recipients. Stratified
analyses were performed to assess for effect
modification. Stratum-specific measures of
association were compared using the Breslow–
Day test. All analyses were performed using SPSS
(IBM, v21.0, Chicago, USA) and SAS (SAS
Institute, v9.1, Cary, USA).
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RESULTS
There were 350 patients who received
daptomycin at a VISN-2 facility. There were
117 patients that were excluded because they
did not receive daptomycin for C48 h or did not
have a CPK level measurement taken while on
therapy. Among the 233 patients that met
inclusion criteria, 180 received daptomycin
alone and 53 received daptomycin while
receiving a statin.
The demographics and clinical
characteristics of the study population are
displayed in Table 1. Overall, the majority of
these baseline characteristics were similar
between the two groups. Mean ± standard
deviation (SD) age was higher (p = 0.02) for
statin recipients (69.7 ± 9.8) than non-
recipients (65.1 ± 13.0). Mean ± SD APACHE-II
scores were also higher (p = 0.04) in statin
recipients (13.9 ± 7.3) than non-recipients
(11.6 ± 6.8). Patients with a higher degree of
renal dysfunction at baseline were more likely
to receive daptomycin while receiving a statin.
With regard to daptomycin use, there were no
statistically significant differences observed in
dose and duration of daptomycin therapy
between groups. The frequency of
concomitant medication use associated with
CPK elevations did not differ significantly
(p = 0.15) between statin users (20.8%) and
non-users (12.8%). No patients were receiving
phenothiazines, chloroquine or
hydroxychloroquine.
Hypertension, congestive heart failure, renal
disease and diabetes were observed more
frequently among statin recipients than non-
recipients. The indications for daptomycin use
had comparable distributions between statin
users and non-users and daptomycin was most
commonly being used to treat bacteremia and
skin and skin structure infections. The most
frequently used statin was simvastatin (58.5%),
followed by atorvastatin (17.0%), pravastatin
(13.2%) and rosuvastatin (11.3%). No patients
received lovastatin, fluvastatin or pitavastatin.
Study outcomes are described in Table 2.
Elevations in CPK levels were observed in a
total of five patients (2.1%). Among these five
patients, 3/53 (5.7%) patients received
daptomycin while receiving a statin, and
2/180 (1.1%) received daptomycin alone
(p = 0.08). No effect modification was observed
by use of other concomitant medications
known to increase CPK values. In the time-to-
event analyses, there was no significant
difference in CPK elevation over time between
statin recipients and non-recipients (p = 0.14).
All patients that had a CPK elevation had a
normal baseline CPK value. Baseline creatinine
clearance also did not affect the development of
CPK elevations. Of patients with creatinine
clearances C30 mL/min, 2.2% experienced a
CPK elevation versus 2.0% of patients with
creatinine clearances \30 mL/min. The
comparison of CPK elevations between
patients who received daptomycin while
receiving a statin and daptomycin alone,
within each of these creatinine clearance
strata, did not differ significantly (Breslow–Day
test p value = 0.47). Although not statistically
significant (p = 0.17), a higher frequency of
death was observed for patients who did not
receive concomitant statin therapy (17.2%)
versus those who were on statin therapy (9.4%).
DISCUSSION
We performed a retrospective cohort study of
Veterans’ Affairs patients that received
daptomycin therapy to assess the relationship
between concomitant statin therapy and CPK
elevation. We observed no significant difference
228 Infect Dis Ther (2014) 3:225–233
Table 1 Bivariate analyses comparing clinical and demographic characteristics among Veterans’ Affairs patients receiving
daptomycin with or without a statin
Covariate No statin
(n5 180)
Statin
(n5 53)
P value
Mean age (SD), years 65.1 (13.0) 69.7 (9.8) 0.02
Male sex, n (%) 173 (96.1) 51 (96.2) 0.97
Mean weight (SD), kg 93.2 (27.2) 93.9 (27.1) 0.88
BMI categories (kg/m2), n (%) 0.54
\20 14 (7.8) 2 (3.8)
20–25 41 (22.8) 15 (28.3)
25–30 45 (25.0) 17 (32.1)
30–35 49 (27.2) 9 (17.0)
35–40 13 (7.2) 4 (7.5)
C40 18 (10.0) 6 (11.3)
Creatinine clearance (mL/min), n (%) 0.04
[90 57 (31.7) 7 (13.2)
60–90 44 (24.4) 13 (24.5)
30–60 44 (24.4) 17 (32.1)
\30 35 (19.4) 16 (30.2)
Patients with any comorbidities associated with CPK elevations, n (%) 172 (95.6) 52 (98.1) 0.40
Organ transplant, n (%) 2 (1.1) 0 (0) 1.00
Musculoskeletal disease, n (%) 13 (7.2) 3 (5.7) 1.00
Hypertension, n (%) 135 (75.0) 52 (98.1) \0.001
Cancer, n (%) 41 (22.8) 11 (20.8) 0.76
CHF, n (%) 25 (13.9) 18 (34.0) 0.001
Renal disease, n (%) 59 (32.8) 27 (50.9) 0.02
Liver disease, n (%) 26 (14.4) 6 (11.3) 0.51
COPD, n (%) 38 (21.1) 12 (22.6) 0.81
Diabetes, n (%) 84 (46.7) 37 (69.8) 0.003
CVA, n (%) 19 (10.6) 10 (18.9) 0.11
Alcoholism, n (%) 24 (13.3) 6 (11.3) 0.70
Prior hospitalization, n (%) 106 (58.9) 34 (64.2) 0.49
Dialysis, n (%) 13 (7.2) 4 (7.5) 1.00
Median (IQR) dose of daptomycin (mg/kg) 6 (5.7–6.3) 5.9 (4.9–6.2) 0.15
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in the frequency of CPK elevation between
statin recipients and non-recipients. Among
patients with a creatinine clearance [30 mL/
min (same type of patients studied in
registration trial [7] and Bhavnani et al. [3]),
there was a lower incidence (2.2%) of CPK
elevation observed than previously reported in
the literature [8–10], irrespective of whether
daptomycin was given with or without a statin.
Bhavnani et al. examined the probability of CPK
elevations in patients who received daptomycin
without a statin and determined the predicted
probability of a CPK elevation to be between
3.73% and 19.5% (at doses ranging from 4 to
Table 1 continued
Covariate No statin
(n5 180)
Statin
(n5 53)
P value
Patients receiving alternative daptomycin dosing frequency
(once every 48 h), n (%)
47 (26.1) 16 (30.2) 0.56
Patients requiring a dose adjustment, n (%) 50 (27.8) 16 (30.2) 0.73
Indication for daptomycin therapy, n (%) 0.25
Skin/soft tissue 53 (29.4) 17 (32.1)
Osteomyelitis 20 (11.1) 9 (17.0)
Endocarditis 17 (9.4) 8 (15.1)
Empiric therapy 14 (7.8) 1 (1.9)
Bacteremia 76 (42.2) 18 (34.0)
Patients with MRSA, n (%) 53 (29.4) 22 (41.5) 0.10
Patients with MSSA, n (%) 20 (11.1) 6 (11.3) 0.96
Patients with VRE, n (%) 64 (35.6) 11 (20.8) 0.04
Median (IQR) time to first daptomycin dose after culture, days 4 (2–9) 4 (2–8) 0.90
Patients in the ICU at initiation of daptomycin, n (%) 54 (30.0) 18 (34.0) 0.58
Mean (SD) APACHE-II score 11.6 (6.8) 13.9 (7.3) 0.04
Median (IQR) baseline CPK value 40 (23–93) 49 (30–101) 0.94
Patient use of other drugs that increase CPK, n (%) 23 (12.8) 11 (20.8) 0.15
Antipsychotics, n (%) 16 (8.9) 6 (11.3) 0.61
Colchicine, n (%) 0 (0) 1 (1.9) 0.23
Corticosteroids, n (%) 7 (3.9) 5 (9.4) 0.11
Antiretrovirals, n (%) 1 (0.6) 0 (0) 1.00
Recreational drugs, n (%) 37 (20.6) 12 (22.6) 0.71
APACHE-II Acute Physiology and Chronic Health Evaluation II, BMI body mass index, CPK creatine phosphokinase,
CHF congestive heart failure, COPD chronic obstructive pulmonary disease, CVA cerebrovascular accident, ICU intensive
care unit, IQR interquartile range, MRSA methicillin-resistant Staphylococcus aureus, MSSA methicillin-sensitive
Staphylococcus aureus, SD standard deviation, VRE vancomycin-resistant Enterococcus
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12 mg/kg/day) [3]. It is interesting to note that
the median (IQR) daptomycin dose in our study
was 6.0 (5.5–6.3) mg/kg and is similar to the
actual dose (6 mg/kg) administered to patients
in the bacteremia/endocarditis registration trial
[7] and the simulations performed by Bhavnani
et al. [3]. The lower frequency of CPK elevations
may denote competing risks or an etiology that
involves varying contributions of exposure,
severity of illness and other clinical factors.
The results of our study are generally
consistent with recently published data
regarding lack of a statistically significant
relationship between CPK elevations and
concomitant use of daptomycin and statin
therapy [2, 8–10]. Parra-Ruiz et al. reported an
8% occurrence of CPK elevation with the
combination of high-dose ([6 mg/kg/day)
daptomycin and statin therapy, and a 10%
occurrence of CPK elevation in patients
receiving daptomycin only [6]. While the
point estimates are higher than those in our
analysis, the comparison resulting in no
difference between the two treatment groups
is largely consistent.
Our study suggests that the incidence of CPK
elevation may be less frequent than previously
reported. This is an interesting finding given
that the population studied included patients
that received care at a VISN-2 facility. The
Veterans’ Affairs population is primarily made
up of patients with a larger distribution of
comorbidities than the general population [11].
Given their underlying health status, this is a
population that one would expect to have a
higher frequency of CPK elevations [12]. These
findings have important implications for
utilization of daptomycin since it may not be
as toxic as previously perceived, regardless of
whether used concomitantly with statin
therapy. Future studies should assess the risk
of CPK elevation in non-VA Medical Center
settings where the volume of comorbidities is
less pronounced.
Although not found to be statistically
significant, daptomycin patients receiving a
Table 2 Clinical outcomes of statin users and non-users among Veterans’ Affairs patients receiving daptomycin
Covariate No statin
(n5 180)
Statin
(n5 53)
P
value
CPK elevation, n (%) 2 (1.1) 3 (5.7) 0.08
Normal baseline CPK (n = 219), n (%) [n = 170] 2 (1.2) [n = 49] 3 (6.1) 0.08
Abnormal baseline CPK (n = 14), n (%) [n = 10] 0 [n = 4] 0 N/A
Median (IQR) day of daptomycin therapy where CPK elevation
occurred
20 (12–28) 28 (16–29) 0.4
Median (IQR) peak CPK value on daptomycin therapy 59 (34–146) 80 (38–168) 0.32
Median (IQR) length of stay at medical center, days 23 (10–59) 28 (14–50) 0.44
Death, n (%) 31 (17.2) 5 (9.4) 0.17
Normal CPK level at baseline was defined as CPK elevation C3 times the upper limit of normal (ULN) and corresponded
to CPK values in excess of 696 units/L. Abnormal CPK level at baseline was defined as a level C5 times ULN (1,160 units/
L)
CPK creatine phosphokinase, IQR interquartile range
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concomitant statin had a lower frequency of
death versus statin non-recipients. These
findings among daptomycin recipients are
consistent with other retrospective studies that
have shown beneficial effects with statin use in
bacteremia, including reduction in all-cause
mortality and bacteremia-related death [13,
14]. Given the lack of relationship between
statin use and CPK elevation and the effect on
mortality, the recommendations surrounding
the concomitant statin use may warrant further
investigation for daptomycin recipients.
Some considerations should be taken into
account when interpreting these findings. First,
only five CPK elevation events were observed
and power may have been an issue indicating
that a larger study needs to be performed.
However, we evaluated all patients that
received daptomycin since FDA approval in
VISN-2. Over 500 patients would have been
required to demonstrate a statistically
significant difference in the small effect size
(5.7% versus 1.1%) observed in our study and
this was not feasible given daptomycin usage in
VISN-2. Due to the very low number of events,
we were unable to perform multivariate analysis
to assess if statin therapy is independently
associated with CPK elevation. Second, we
were unable to discriminate the CPK risk
associated with individual statins because the
majority of patients were on the VA formulary
agent, simvastatin, during the study period.
Third, some patients who did not receive statin
therapy while receiving daptomycin had
previous exposure to statins. It is unclear
whether previous exposure would affect the
risk of developing a CPK elevation. Future
studies should discern whether this is an
important predictor. Fourth, this study was
performed among patients receiving care at
VISN-2 facilities. External validity may be an
issue in populations with a different
distribution of comorbidities and gender.
Finally, none of the CPK events occurred in
patients on hemodialysis. This is an important
point to consider because these patients are
likely to have altered drug exposure and
potentially have a higher probability of
achieving troughs in excess of 24.3 lg/mL, the
threshold associated with an elevated risk of
CPK elevations [3]. Given that this trough target
was derived from patients enrolled in
registration trials of daptomycin, future studies
should evaluate if this trough threshold is
applicable to the general population of
patients using daptomycin and if the
threshold differs by use of concomitant statin
therapy, hemodialysis and other clinical factors
that may modify daptomycin exposure.
In summary, the incidence of CPK elevation
did not significantly differ with or without
concomitant statin therapy among patients
receiving daptomycin. Previous
recommendations to avoid this combination
should be revisited given these findings. Future
studies should examine this relationship in
larger populations with more heterogeneous
statin usage and attempt to quantify the risk
of CPK elevation with individual statins.
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